IN8bio opened higher at $0.88, compared with its previous close of $0.87. In the last trading session, the stock traded between $0.81 and $0.88. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in IN8bio is now worth
$ 0.34
Resulting in a loss of
$ 99.66 (99.66%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.03 (-3.64%)
Day High
$0.88
Day Low
$0.81
Day Open
$0.88
Prev Close
$0.87
Volume
14,817
1W Return
-10.73%
1M Return
-32.26%
3M Return
-19.23%
6M Return
-48.31%
1Y Return
-50.00%
Fundamentals
Market Cap ($ Mn)
9
PE Ratio
-
PB Ratio
0.56
PEG Ratio
-
ROE
-115.25%
ROCE
-102.69%
EPS (TTM)
$-0.49
Investment Returns
1 Week
-10.73%
1 Month
-32.26%
3 Months
-19.23%
6 Months
-48.31%
9 Months
-57.79%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
Updates
7Oct
IN8bio grants 60,000 stock options to new employee under inducement plan
IN8bio granted 60,000 nonqualified stock options to a single new employee. The award was issued under the 2026 Inducement Plan with a grant date of October 1, 2026. Options vest over four years, with 25% cliffing at the one-year mark. The grant complies with Nasdaq Listing Rule 5635(c)(4) for inducement awards.
1mo ago
11Aug
IN8bio grants 4,000 stock options to new employee
IN8bio Inc. granted 4,000 stock options to a new employee under Nasdaq Listing Rule 5635(c)(4) as an inducement to hire. The Compensation Committee approved the award on August 3, 2026, with a four-year vesting schedule including a one-year cliff. This move supports the company's talent acquisition strategy for its clinical-stage pipeline development.
3mo ago
7Aug
IN8bio Q2 EPS $(0.25) beats $(0.37) estimate on cost control
IN8bio Inc. beat Q2 EPS estimates with $(0.25) per share, a 32.43% improvement over the $(0.37) consensus. The company narrowed its net loss to $4.8 million and increased cash to $18.0 million, supporting clinical progress in glioblastoma.
3mo ago
9Jul
IN8bio publishes Phase 1 INB-200 data in Journal of Clinical Oncology
IN8bio, Inc. published Phase 1 data for INB-200 in The Journal of Clinical Oncology, showing promising results for its DeltEx DRI therapy in glioblastoma patients. Repeat-dose patients achieved a median progression-free survival of 16.1 months, more than double the standard of care benchmark, with no significant toxicities reported.
